Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse model
Tomoatsu Ikeya(Shizuoka Cancer Center), Yasuto Akiyama(Shizuoka Cancer Center)
Cited by 1
Related Papers
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell Line
|Cancer Genomics & Proteomics|2017|41